Brind.

Pfizer and Arvinas announced a partnership to co-develop Vepdegestrant.

3 reports, 2 independent Updated Aug 23

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Pfizer and Arvinas announced a partnership to co-develop Vepdegestrant.

Who's involved

What this event is mainly about

Pfizer Arvinas (United States)

Keep exploring

The entities involved

Pfizer
American multinational pharmaceutical and biotechnology corporation
- Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Mon 05:00
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
Arvinas (United States)
company in New Haven, United States
- Trump pledged to unleash American oil and gas production, involving LCNB National Bank.Sun 03:20

Related events

Coverage

Newest first; wire copies grouped

Aug 23Insider MonkeyArvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX Topco Arvinas, Inc. (NASDAQ:ARVN) is among the best US stocks under $10 to invest in. XTX Topco Ltd has increased its stake in Arvinas, Inc. (NASDA
Aug 18Insider MonkeyArvinas, Pfizer’s Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in
Aug 6GlobeNewswireArvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic bre